• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Metacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders

    3/24/23 5:28:02 PM ET
    $MTCR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTCR alert in real time by email
    8-K
    true NONE false 0001634379 0001634379 2023-03-23 2023-03-23

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 23, 2023

     

     

    Metacrine, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39512   47-2297384

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    4225 Executive Square, Suite 600

    San Diego, California

      92037
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (858) 369-7800

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.0001 per share   None   None

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company  ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

     

     

     


    Item 3.03

    Material Modification to Rights of Security Holders.

    On March 24, 2023, Metacrine, Inc. (the “Company”) filed a certificate of dissolution (the “Certificate of Dissolution”) with the Secretary of State of the State of Delaware that became effective upon filing and is intended to effect the complete liquidation and dissolution of the Company in accordance with (i) Section 275 and other applicable provisions of the General Corporation Law of the State of Delaware (the “DGCL”) and applicable provisions of the Internal Revenue Code of 1986, as amended (the “Dissolution”) and (ii) the Plan of Dissolution (“Plan of Dissolution”) approved by the Company’s board of directors (the “Board”) on January 24, 2023 and the Company’s stockholders on March 23, 2023. Pursuant to Section 278 of the DGCL, the Company’s existence will continue for a period of at least three years for the purpose of prosecuting and defending suits and to enable the Company gradually to sell its properties and to wind up its affairs and discharge its liabilities.

     

    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Resignation and Appointment of Directors

    On March 23, 2023, in furtherance of the Plan of Dissolution, each of the Company’s directors submitted their resignation from the Board and the committees thereof opposite their name below, effective as of 11:59 p.m. Pacific Time on March 23, 2023 (the “Director Resignation Time”).

     

      •  

    Richard Heyman, Ph.D. (Compensation Committee and Nominating and Corporate Governance Committee)

     

      •  

    Ronald Evans, Ph.D.

     

      •  

    Julia Owens, Ph.D. (Compensation Committee)

     

      •  

    Andrew Guggenhime (Audit Committee)

     

      •  

    Jeffrey Jonker (Audit Committee and Nominating and Corporate Governance Committee)

     

      •  

    Preston Klassen, M.D.

     

      •  

    John McHutchison, M.D. (Compensation Committee)

     

      •  

    Amir Nashat, Ph.D. (Audit Committee)

    None of the resignations were related to any disagreement with the Company over any of its operations, policies or practices.

    On March 23, 2023, prior to the Director Resignation Time, the Board (i) increased the authorized number of directors from eight (8) to nine (9) and (ii) appointed H. Michael Hogan as a member of the Board, to serve until his successor is duly elected and qualified or until his earlier death, resignation or removal. Following the appointment of Mr. Hogan, the Board decreased the authorized number of directors from nine (9) to one (1), effective as of the Director Resignation Time.

    Mr. Hogan, age 60, has served as a Partner at Armanino LLP (“Armanino”), a top 20 U.S. full-service firm providing tax, assurance and consulting services to clients in the nation’s emerging markets, since January 2021, and leads the firm’s Corporate Finance and Restructuring practices. From October 2016 to January 2021, Mr. Hogan served as a Managing Director in the firm’s Corporate Finance and Restructuring practice. Prior to his time at Armanino, Mr. Hogan served as a Managing Director at Sherwood Advisory Services, with a focus on advisory and managerial services for distressed companies.

    Mr. Hogan has over 30 years of diverse experience in operations, finance and strategy roles, and specializes in assessing strategic options, stabilizing and turning around underperforming businesses and driving exits, by improving operations and margins, refocusing strategy, negotiating debt structuring/renegotiations, increasing cash flow and managing expenditures with focused leadership and control. Mr. Hogan received a B.A. in Political Science and Economics from Colgate University.

    Appointment of President and Chief Executive Officer

    As previously disclosed, on March 17, 2023, Michael York notified the Board of his resignation from his positions as the Company’s President, Chief Executive Officer, Chief Business Officer, principal financial officer, principal accounting officer, secretary and treasurer, effective as of 11:59 p.m. Pacific Time on March 24, 2023 (the “Officer Resignation Time”).


    On March 24, 2023, in furtherance of the Plan of Dissolution, the Board appointed Dave Maggio to the positions of President, Chief Executive Officer, Secretary and Treasurer, and designated Mr. Maggio as the Company’s principal executive officer, principal financial officer and principal accounting officer, in each case effective as of the Officer Resignation Time.

    Mr. Maggio, age 64, has served as a Director at Armanino in the firm’s Corporate Finance and Restructuring practice since November 2021. Previously, he was a Co-Founder of Omni Professional Services, LLC, a privately owned investor in the sporting goods industry headquartered in El Paso, Texas, and has served as an Operating Partner at CornerPost Capital,Partners, LLC, a middle-market, private equity firm based in Dallas, Texas, since 2010. Mr. Maggio has served on the board of directors of TGE Industrial Services, LLC, a privately held company focused on servicing the petrochemical, refining, chemical and heavy manufacturing industries since 2013, and in late 2018, during his tenure as Chief Executive Officer, negotiated a strategic merger with an industry peer. He was previously with Price Waterhouse/PricewaterhouseCoopers Investment Banking in Houston, Texas and San Jose, California.

    Mr. Maggio has over 35 years of domestic and global experience in executing financial advisory, turnaround and restructuring assignments, as well as strategically focused corporate finance and M&A projects. He focuses on serving small to mid-market companies with deals up to $250 million in the U.S., Europe and Asia. Mr. Maggio received a B.S. in Accounting from Louisiana State University and completed the Northwestern/Kellogg Business School Executive Merger & Acquisitions Program.

    There were no arrangements or understandings between Mr. Hogan or any other persons regarding his appointment to the Board, nor is either Mr. Hogan or Mr. Maggio party to any related party transactions required to be reported pursuant to Item 404(a) of Regulation S-K, except as set forth below:

     

      •  

    In January 2023, the Company entered into an engagement letter with Armanino, where Mr. Maggio serves as a Director and Mr. Hogan serves as a Partner, pursuant to which Armanino provides business operations management, consulting and other professional services to the Company in furtherance of the Plan of Dissolution. The Company has incurred approximately $64,000 of fees for professional services, including a $20,000 retainer, provided by Armanino to date.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    On March 23, 2023, the Company held a special meeting of stockholders (the “Special Meeting”). The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Special Meeting are set forth below. The proposals set forth below are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on February 13, 2023.

    Proposal 1: The consummation of the Dissolution in accordance with the Plan of Dissolution was approved, based on the following votes:

     

    For

      

    Against

      

    Abstain

      

    Broker Non-Votes

    23,852,140    658,607    5,104    —

    Proposal 2: The adjournment from time to time of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes to approve the Plan of Dissolution was approved, based on the following votes:

     

    For

      

    Against

      

    Abstain

      

    Broker Non-Votes

    23,737,870    741,677    36,304    —


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        METACRINE, INC.
    Date: March 24, 2023     By:  

    /s/ Michael York

          Michael York
          President and Chief Executive Officer
    Get the next $MTCR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MTCR

    DatePrice TargetRatingAnalyst
    10/22/2021$2.50Outperform → Sector Perform
    RBC Capital Mkts
    10/22/2021$19.00 → $1.00Buy → Hold
    Canaccord Genuity
    10/22/2021$14.00 → $2.00Buy → Hold
    Jefferies
    10/22/2021Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $MTCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Metacrine downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Metacrine from Outperform to Sector Perform and set a new price target of $2.50

      10/22/21 7:43:25 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Metacrine from Buy to Hold and set a new price target of $1.00 from $19.00 previously

      10/22/21 7:42:38 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine downgraded by Jefferies with a new price target

      Jefferies downgraded Metacrine from Buy to Hold and set a new price target of $2.00 from $14.00 previously

      10/22/21 7:42:07 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement

      LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www.sec.gov and on Metacrine's website under the heading "Investors." About Metacrine Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies t

      12/23/22 4:01:00 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine Reports Third-Quarter 2022 Results

      SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. "We made great progress during the quarter in advancing our proposed merger with Equillium," said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. "We believe that Equillium has demonstrated compelling clinical data in Lupus Nephritis and has an exciting pipeline of clinical programs with multiple upcoming data catalysts and potential value inflection events. Equillium is led by an accomplished leadership

      11/14/22 4:38:48 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Equillium to Acquire Metacrine in All-Stock Transaction

      Expected to add $33 million in cash at closing to Equillium's balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors Equillium, Inc. (NASDAQ:EQ) and Metacrine Inc. (NASDAQ:MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024.

      9/6/22 4:00:00 PM ET
      $EQ
      $MTCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products

    $MTCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Klassen Preston

      4 - Metacrine, Inc. (0001634379) (Issuer)

      3/24/23 12:35:32 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: York Michael sold $44,331 worth of shares (107,054 units at $0.41), decreasing direct ownership by 51% to 103,499 units (tax withholding)

      4 - Metacrine, Inc. (0001634379) (Issuer)

      1/27/23 4:44:04 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: Klassen Preston sold $157,266 worth of shares (380,605 units at $0.41), decreasing direct ownership by 41% to 541,905 units (tax withholding)

      4 - Metacrine, Inc. (0001634379) (Issuer)

      1/27/23 4:42:52 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Metacrine Inc.

      15-12G - Metacrine, Inc. (0001634379) (Filer)

      3/24/23 5:29:55 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Metacrine, Inc. (0001634379) (Filer)

      3/24/23 5:28:02 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-8 POS filed by Metacrine Inc.

      S-8 POS - Metacrine, Inc. (0001634379) (Filer)

      3/23/23 4:34:58 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Financials

    Live finance-specific insights

    See more
    • Equillium to Acquire Metacrine in All-Stock Transaction

      Expected to add $33 million in cash at closing to Equillium's balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors Equillium, Inc. (NASDAQ:EQ) and Metacrine Inc. (NASDAQ:MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024.

      9/6/22 4:00:00 PM ET
      $EQ
      $MTCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products

    $MTCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)

      SC 13G/A - Metacrine, Inc. (0001634379) (Subject)

      2/14/23 4:00:28 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)

      SC 13G/A - Metacrine, Inc. (0001634379) (Subject)

      2/8/23 3:43:35 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Metacrine Inc.

      SC 13G - Metacrine, Inc. (0001634379) (Subject)

      12/19/22 4:00:11 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Metacrine Announces Resignation of Chief Medical Officer

      SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to pursue a new opportunity. Dr. Chen's resignation is effective December 31, 2021. Preston Klassen, M.D., MHS, chief executive officer, is expected to assume responsibility for Metacrine's ongoing clinical trials and future clinical operations. "We appreciate Hubert's significant contributions during the last three years as we moved our pipeline through several important milestones," said Preston Klass

      12/27/21 8:00:00 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors

      SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced the appointment of Julia C. Owens, Ph.D. to the Company’s board of directors, effective April 1, 2021. Dr. Owens will serve as a member of the Compensation Committee.   “We’re excited to welcome Julia as a new independent director,” commented Richard Heyman, Ph.D., Metacrine’s chairman. “She is an accomplished biopharmaceutical executive, with an established track record in building companies, business development, capital formation and strategic partnerships. Juli

      4/5/21 4:05:00 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care